Skip to main content
construction release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel
Journal cover image

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

Publication ,  Journal Article
Wagner, LM
Published in: Clin Sarcoma Res
2015

Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents.

Duke Scholars

Published In

Clin Sarcoma Res

DOI

ISSN

2045-3329

Publication Date

2015

Volume

5

Start / End Page

20

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wagner, L. M. (2015). Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res, 5, 20. https://doi.org/10.1186/s13569-015-0035-x
Wagner, Lars M. “Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?Clin Sarcoma Res 5 (2015): 20. https://doi.org/10.1186/s13569-015-0035-x.
Wagner, Lars M. “Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?Clin Sarcoma Res, vol. 5, 2015, p. 20. Pubmed, doi:10.1186/s13569-015-0035-x.
Journal cover image

Published In

Clin Sarcoma Res

DOI

ISSN

2045-3329

Publication Date

2015

Volume

5

Start / End Page

20

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis